Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Saniona AB (publ), a rare disease biopharmaceutical company, engages in the research, development, and commercialization of treatments for the central nervous system in Denmark. The company's products include Tesofensine, a monoamine reuptake inhibitor; and Tesomet, a fixed dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBIT
Target Price
The average target price of SANION.ST is 19 and suggests 10% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to
Buy
Sell